Daclacure 60mg Tablet

Chronic hepatitis C virus (HCV) infection

The human body reacts differently to Declacure 60mg tablet. Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately. Some of the common side effects of Declacure 60mg tablet are mentioned below: Headache

Nausea

Unusual tiredness

Anemia

Insomnia

Dizziness

Shortness of breath

Irregular heartbeat

Chest pain

Fatigue Allergic reaction

Upset stomach

Trouble sleeping

Memory problems

Low blood sugar

Vomiting

Abdominal cramps

Swelling of the mouth, face, tongue, or throat

Take the dose of Declacure 60mg tablet as per your healthcare provider’s prescription. Do not stop taking the medicine suddenly, unless your doctor tells you.This medicine is given under the strict supervision of a doctor. Do not self-administer. Overdose is a very unusual state for this medicine because it is given under the supervision of a healthcare provider. Declacure 60mg tablet can be taken without food or with food. The doctor will provide emergency medical treatment. You should not break, crush, or chew the medicine; it should be swallowed as a whole.

An antiviral medication, Daclacure tablet, is used for the treatment of Hepatitis C virus (HCV) infection. It works by lowering the viral load from the blood; as a result, Infected individuals feel relief from the related symptoms of the chronic hepatitis C infection. Daclacure tablet causes a decrease in serum RNA levels of HCV by stopping the function of the nonstructural protein 5A (NS5A) protein in the replication complex. The effect of this medicine can be easily seen within 2 hours after its oral administration.

It is advisable not to miss a dose of Daclatasvir Dihydrochloride 60mg Tablet. If you miss a scheduled dose of this medicine, contact your doctor immediately.

Gandhi Y, Eley T, Fura A, Li W, Bertz RJ, Garimella T. (2024). Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics. Clin Pharmacokinet. 57(8):911-928.

Eley T, Garimella T, Li W, Bertz RJ. (2023). Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions. Clin Pharmacokinet. 54(12):1205-22.

Talavera Pons S, Boyer A, Lamblin G, Chennell P, Châtenet FT, Nicolas C, Sautou V, Abergel A. (2025). Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C. Br J Clin Pharmacol. 83(2):269-293.

Kiang TKL. (2024). Clinical Pharmacokinetics and Drug-Drug Interactions of Elbasvir/Grazoprevir. Eur J Drug Metab Pharmacokinet. 43(5):509-531.

Feng HP, Guo Z, Ross LL, Fraser I, Panebianco D, Jumes P, Fandozzi C, Caro L, Talaty J, Ma J, Mangin E, Huang X, Marshall WL, Butterton JR, Iwamoto M, Yeh WW. (2023). Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir. J Antimicrob Chemother. 74(3):710-717.

De Bellis E, Donnarumma D, Zarrella A, Mazzeo SM, Pagano A, Manzo V, Mazza I, Sabbatino F, Corbi G, Pagliano P, Filippelli A, Conti V. (2024). Drug-Drug Interactions Between HIV Antivirals and Concomitant Drugs in HIV Patients: What We Know and What We Need to Know. Pharmaceutics. 17(1):31.

Priyanka PSSL, Varma DM, Immadisetti K, Rajesh R, Vidyasagar S, Guddattu V. (2023). Recognition of possible risk factors for clinically significant drug-drug interactions among Indian people living with HIV receiving highly active antiretroviral therapy and concomitant medications. Int J Risk Saf Med. 29(1-2):25-55.